Stoke Therapeutics, Inc.
STOK- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001623526
In the last 90 days, Stoke Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 197 institutions reported holding it in 13F filings for Q2 2026, worth $2.49B in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Stoke Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 100 | 1 | 97 | −2 |
| Shares | 46.5M | 300 | 43.8M | −2.72M (−5.8%) |
| Value | $494.8M | $2.00K | $173.1M | −$321.6M (−65.0%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Stoke Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Lynx1 Capital Management LP | 1,710,154 | $6.74M | 4.46% |
| Jacobs Levy Equity Management, Inc | 217,605 | $857.4K | 0.01% |
| Walleye Capital LLC | 67,351 | $265.4K | 0.00% |
| Marshall Wace, LLP | 48,001 | $189.1K | 0.00% |
| Ameriprise Financial Inc | 33,032 | $130.1K | 0.00% |
| Public Employees Retirement System of Ohio | 16,335 | $64.0K | 0.00% |
| American Century Companies Inc | 16,143 | $63.6K | 0.00% |
| Verition Fund Management LLC | 15,255 | $60.1K | 0.00% |
| Squarepoint Ops LLC | 15,210 | $59.9K | 0.00% |
| Corton Capital Inc. | 14,749 | $58.1K | 0.03% |
| Two Sigma Advisers, LP | 13,800 | $54.4K | 0.00% |
| SG Americas Securities, LLC | 13,557 | $53.0K | 0.00% |
| Sherbrooke Park Advisers LLC | 12,295 | $48.4K | 0.02% |
| Dorsey & Whitney Trust CO LLC | 10,815 | $42.6K | 0.00% |
| Federated Hermes, Inc. | 1,076 | $4.24K | 0.00% |
| Cutler Group LP | 600 | $2.00K | 0.00% |
| Provence Wealth Management Group | 470 | $1.85K | 0.00% |
Sold out (19)
Institutions that held Stoke Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| M28 Capital Management LP | 346,190 | $3.68M |
| Artal Group S.A. | 250,000 | $2.66M |
| Octagon Capital Advisors LP | 185,669 | $1.97M |
| Driehaus Capital Management LLC | 102,489 | $1.09M |
| Schonfeld Strategic Advisors LLC | 62,902 | $668.6K |
| Connor, Clark & Lunn Investment Management Ltd. | 45,575 | $484.5K |
| Renaissance Technologies LLC | 42,300 | $450.0K |
| TD Asset Management Inc | 26,186 | $278.4K |
| Norges Bank | 24,700 | $262.6K |
| PDT Partners, LLC | 23,592 | $250.8K |
| Belvedere Trading LLC | 15,783 | $167.8K |
| Boothbay Fund Management, LLC | 14,180 | $150.7K |
| Franklin Resources Inc | 12,643 | $134.4K |
| Russell Investments Group, Ltd. | 1,382 | $14.7K |
| Signaturefd, LLC | 1,031 | $11.0K |
| Lindbrook Capital, LLC | 412 | $4.38K |
| EverSource Wealth Advisors, LLC | 127 | $1.35K |
| Advisor Group Holdings, Inc. | 100 | $1.06K |
| Parallel Advisors, LLC | 57 | $606 |
Not filed for Q3 2023 yet (1)
Institutions that held Stoke Therapeutics, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Endurance Wealth Management, Inc. | 300 | $2.00K |